AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Myosin-7B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

A7E2Y1

UPID:

MYH7B_HUMAN

Alternative names:

Antigen MLAA-21; Myosin cardiac muscle beta chain; Myosin heavy chain 7B, cardiac muscle beta isoform; Slow A MYH14

Alternative UPACC:

A7E2Y1; Q5JVW7; Q6NT44; Q6NT57; Q6WG75; Q96I57; Q9NWE2; Q9P216

Background:

Myosin-7B, known by alternative names such as Antigen MLAA-21, Myosin cardiac muscle beta chain, and Myosin heavy chain 7B, cardiac muscle beta isoform, plays a crucial role in muscle contraction. This protein's involvement in the fundamental process of muscle contraction highlights its importance in maintaining cardiac muscle function and overall cardiovascular health.

Therapeutic significance:

Understanding the role of Myosin-7B could open doors to potential therapeutic strategies. Its critical function in muscle contraction suggests that targeting Myosin-7B could lead to innovative treatments for cardiac disorders, offering hope for improved patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.